Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Givinostat - Italfarmaco

Next Previous
X
Search
Drug Profile

Givinostat - Italfarmaco

Alternative Names: DUVYZAT; Givinostat hydrochloride hydrate- Italfarmaco; Givinostat hydrochloride monohydrate - Italfarmaco; ITF-2357

Latest Information Update: 30 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Italfarmaco; Sanford Burnham Prebys Medical Discovery Institute
  • Developer Italfarmaco
  • Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Benzene derivatives; Carbamates; Ethylamines; Hydroxamic acids; Naphthalenes; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duchenne muscular dystrophy
  • Phase III Polycythaemia vera
  • Phase II Myeloproliferative disorders
  • Discontinued Chronic lymphocytic leukaemia; Crohn's disease; Diffuse large B cell lymphoma; Hereditary autoinflammatory diseases; Hodgkin's disease; Juvenile rheumatoid arthritis; Multiple myeloma

Most Recent Events

  • 25 Jul 2024 Launched for Duchenne muscular dystrophy (In adolescents, In children, In adults) in USA (PO)-First global approval
  • 28 May 2024 No recent reports of development identified for phase-I development in Polycythaemia-vera(In volunteers) in Canada (PO, Suspension)
  • 26 Mar 2024 Chemical structure information updated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top